MedTrace Logo

Expanded Access to Provide SUVN-502 for the Treatment of Subjects With Alzheimer's Disease

NCT03564964 · Status: NO_LONGER_AVAILABLE · Type: EXPANDED_ACCESS

Last updated 2020-09-29

No results posted yet for this study

Summary

This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to SUVN-502 for the treatment of Alzheimer's Disease. Investigator as well as the subject/caregiver must decide whether the potential benefit outweighs the risk of receiving an investigational therapy based on the patient's medical history and program eligibility criteria.

Subjects will not be evaluated for efficacy and safety during the expanded access.

Conditions

  • Alzheimer Disease
  • Dementia
  • Cognition Disorders

Interventions

DRUG

SUVN-502

Tablet

Sponsors & Collaborators

  • Suven Life Sciences Limited

    lead INDUSTRY

Eligibility

Min Age
50 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03564964 on ClinicalTrials.gov